A bovine model for examining the effects of an aromatase inhibitor on ovarian function in women

被引:19
|
作者
Yapura, Jimena [1 ]
Mapletoft, Reuben J. [2 ]
Pierson, Roger [3 ]
Singh, Jaswant [1 ]
Naile, Jonathan [4 ]
Giesy, John P. [1 ,4 ]
Adams, Gregg P. [1 ]
机构
[1] WCVM, Dept Vet Biomed Sci, Saskatoon, SK S7N 5B4, Canada
[2] WCVM, Dept Large Anim Clin Sci, Saskatoon, SK S7N 5B4, Canada
[3] Univ Saskatchewan, Coll Med, Dept Obstet Gynecol & Reprod Sci, Saskatoon, SK S7N 0W0, Canada
[4] Univ Saskatchewan, Toxicol Ctr, Saskatoon, SK, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Aromatase; aromatase inhibitor; bovine model; corpus luteum; dominant follicle; estrogens; follicular dynamics; letrozole; ovary; LUTEINIZING-HORMONE; FOLLICULAR DYNAMICS; CLOMIPHENE CITRATE; DOMINANT FOLLICLE; MENSTRUAL-CYCLE; LETROZOLE; HEIFERS; ENDOCRINE; CATTLE; STIMULATION;
D O I
10.1016/j.fertnstert.2011.05.038
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To test the hypothesis that treatment with an aromatase inhibitor (letrozole) will terminate dominant ovarian follicle growth and result in the emergence of a new follicular wave, regardless of the stage of follicular development at the time of treatment. Design: Prospective study. Setting: Academic research center. Animal(s): Postpubertal beef heifers. Intervention(s): Randomized trial involving treatment with letrozole on days 1-3, 3-5, 5-7 (day 0 = pretreatment ovulation) or no treatment. Main Outcome Measure(s): Follicular development, corpus luteum (CL) development, hormone profiles, and plasma aromatase inhibitor concentration. Result(s): Multiple doses of letrozole lengthened the period of follicular dominance, delayed emergence of the next follicular wave, and resulted in a larger CL regardless of the stage of the follicular wave in which treatments were initiated. No effects on circulating FSH concentrations were detected, but the stimulatory effects on the dominant follicle and CL were associated with increased plasma concentrations of LH in letrozole-treated animals. Plasma P concentrations were numerically higher throughout the luteal phase in letrozole-treated versus control heifers, but differences were not significant. Conclusion(s): The results provide rationale for the hypothesis that the mechanism of action responsible for the stimulatory effect of aromatase inhibitors on ovarian function involves an elevation in circulating concentrations of LH rather than FSH. (Fertil Steril (R) 2011;96:434-8. (C) 2011 by American Society for Reproductive Medicine.)
引用
收藏
页码:434 / U507
页数:8
相关论文
共 50 条
  • [41] The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy
    Barbara, Mayr
    Bernhard, Reich
    Richard, Greil
    Josef, Niebauer
    CANCER MEDICINE, 2022, 11 (24): : 4946 - 4953
  • [42] Direct effects of the algal toxin, domoic acid, on ovarian function: Bovine granulosa and theca cells as an in vitro model
    Pizzo, Fabiola
    Caloni, Francesca
    Schreiber, Nicole B.
    Schutz, Luis F.
    Totty, Morgan L.
    Albonico, Marco
    Spicer, Leon J.
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2015, 113 : 314 - 320
  • [43] Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
    Dowsett, M
    Pfister, C
    Johnston, SRD
    Miles, DW
    Houston, SJ
    Verbeek, JA
    Gundacker, H
    Sioufi, A
    Smith, IE
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2338 - 2343
  • [44] EFFECTS OF ANAT BANIEL METHOD® NEUROMOVEMENT® LESSONS ON WOMEN WITH BREAST CANCER TREATED WITH AN AROMATASE INHIBITOR
    Pederson, Julie
    Hunt, Sheila
    Hollingsworth, Tyler
    Cisneros, Tracy
    Rivers, Shelby
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [45] Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer
    Oktay, Kutluk
    Turan, Volkan
    Kim, Jayeon
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation.
    Mitwally, MF
    Casper, RF
    FERTILITY AND STERILITY, 2002, 78 (03) : S277 - S278
  • [47] Profound Reduction of Ovarian Estrogen by Aromatase Inhibition in Obese Women
    Ross, Lauren A.
    Polotsky, Alex J.
    Kucherov, Alexander
    Bradford, Andrew P.
    Lesh, Jennifer
    Chosich, Justin
    Gee, Nancy
    Santoro, Nanette
    OBESITY, 2014, 22 (06) : 1464 - 1469
  • [48] Compensatory Increase in Ovarian Aromatase in Older Regularly Cycling Women
    Shaw, N. D.
    Srouji, S. S.
    Welt, C. K.
    Cox, K. H.
    Fox, J. H.
    Adams, J. A.
    Sluss, P. M.
    Hall, J. E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (09): : 3539 - 3547
  • [49] THE EFFECTS OF BUSERELIN MICROPARTICLES ON OVARIAN-FUNCTION IN HEALTHY WOMEN
    MEYER, BH
    MULLER, FO
    DELAREY, N
    LUUS, HG
    ROSENKRANZ, B
    SOUTH AFRICAN MEDICAL JOURNAL, 1995, 85 (08): : 766 - 767
  • [50] EFFECTS OF HMG POSTOVULATORY ADMINISTRATION ON OVARIAN-FUNCTION IN WOMEN
    CORTESPR.J
    ORIOLBOS.A
    REPRODUCCION, 1974, 1 (02): : 171 - 175